The Latest Breaking News from Truist

New Street analyst Pierre Ferragu upgraded NVIDIA Corp (NASDAQ:NVDA) to Buy from Neutral with a price target of $280 (30.2% upside). Ferragu saw an attractive valuation, greater visibility on the "crypto-winter risk," and the company's robust data center outlook.  Ethereum's hash rate quadrupled between October 2020 and January 2022, likely boosting Nvidia's FY22 gaming revenues…

BofA analyst Vivek Arya reiterated a Buy rating and a $375 price target (71.1% upside) on NVIDIA Corp (NASDAQ:NVDA) and a Top Pick designation. Arya saw the Baird downgrade-related selloff as likely done. Truist also slashed the price targets on the chipmakers. Arya acknowledged that Nvidia's gaming business was vulnerable to weaker demand from Europe due to the Russia-Ukraine…

Analysts mainly slashed the price targets or downgraded the rating on Blend Labs Inc (NYSE:BLND) post Q4 results. KeyBanc analyst Josh Beck lowered the price target to $6 from $10 (26% upside) and kept an Overweight.  The company's FY22 revenue forecast was well below the Street's $343.8 million, reflecting the negative impact of higher rates…

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal.  Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

Analysts painted sharp upside to GitLab Inc (NASDAQ:GTLB) post strong Q4 results that included a notable top-line beat and FY23 guidance ahead of Street expectations. Truist analyst Joel Fishbein lowered the PT to $105 from $175 (217.2% upside) and kept a Buy, citing the change in discount rate assumptions since the IPO.  KeyBanc analyst Michael Turits lowered…

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ:VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading at about 2-times cash, the stock is "undervalued" given its programs in two cancers. Devarakonda adds that the Verastem base case is supported by a…

Analysts slashed their price targets on Roku Inc (NASDAQ:ROKU) post Q4 results. Pivotal Research analyst Jeffrey Wlodarczak downgraded to Sell from Hold with a PT of $95, down from $350 (34.4% downside).  The company reported an "overall mixed" Q4 as it issued a lower than forecast 2022 revenue outlook and decided to "massively ramp" operating expenses,…

Piper Sandler analyst Harsh Kumar reiterated an Overweight rating and $350 price target on NVIDIA Corp (NASDAQ:NVDA). Nvidia could be a big winner this earnings season, with profits driven by solid performance in the chip maker's gaming and data center businesses, Kumar said. "We are looking for a significant beat and raise when the company…

Truist analyst Matthew Thornton reiterated the Buy rating and $690 price target ahead of Netflix Inc's (NASDAQ:NFLX) Q4 earnings announcement on January 20. The price target implies an upside of 34%. Sentiment on the stock is "cautious," with buy-side investors anticipating net adds as low as 6.3 million, Thornton notes.  Related Content: Read How Analysts View…